Market Size of France Diabetes Drugs Industry
| Study Period | 2018 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Market Size (2024) | USD 1.42 Billion |
| Market Size (2029) | USD 1.67 Billion |
| CAGR (2024 - 2029) | 3.22 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
France Diabetes Drugs Market Analysis
The France Diabetes Drugs Market size is estimated at USD 1.42 billion in 2024, and is expected to reach USD 1.67 billion by 2029, growing at a CAGR of 3.22% during the forecast period (2024-2029).
Diabetic drugs are medicines developed to stabilize and control blood glucose levels amongst people with diabetes. Diabetic drugs have been potential candidates for treating diabetic patients affected by SARS-CoV-2 infection during the COVID-19 pandemic. Diabetes has the highest prevalence among all chronic conditions covered 100% by France's statutory health insurance (SHI), and the number of covered patients has doubled in the past 10 years. France is one of the major countries in the Europe region.
According to the World Health Organization (WHO), about a million are diagnosed with diabetes in France. The prevalence of diabetes is growing among all ages in France, which can be attributed to the growing obese population, along with unhealthy diets and sedentary lifestyles of people.
Thus, the rising prevalence of diabetes and obesity, growing awareness, regarding diabetic care, healthcare expenditure, and technological advancements are a few factors that are further driving the market for diabetes drugs in France. In France, there is a centralized health care system their all the reimbursement decisions are taken at a national level and then applies to all the countries.
Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.
